Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
3,960
datasets available to search
ShareScore release 0.9.0
Dataset results
3,960 results for “lung patient”
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT01355484. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
ClinicalTrials.gov study NCT00694603. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT00729612. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients
ClinicalTrials.gov study NCT00671723. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Lifestyle Modification Program for Lung Cancer Patients - Physical Activity Preference
ClinicalTrials.gov study NCT04104516. IPD Sharing: NO. Countries: 1. Publications: 3.
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
ClinicalTrials.gov study NCT02597933. IPD Sharing: Not stated. Countries: 32. Publications: 15.
Lifestyle Modification Program for Lung Cancer Patients - A Pilot Study
ClinicalTrials.gov study NCT04105647. IPD Sharing: NO. Countries: 1. Publications: 2.
Chemotherapy for Patients With Non-Small Cell Lung Cancer (NSCLC)
ClinicalTrials.gov study NCT00391274. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Minimizing Pathologic Aspiration in Patients Undergoing Esophageal and Lung Resections for Cancer
ClinicalTrials.gov study NCT04251312. IPD Sharing: NO. Countries: 1. Publications: 3.
BDP/FF Versus Formoterol Fumarate (FF) in Patients With Severe COPD (Lung Function and Exacerbation Rate)
ClinicalTrials.gov study NCT00929851. IPD Sharing: YES. Countries: 1. Publications: 4.
HINC dataset from: Homeopathic treatment as an add-on therapy may improve quality of life and prolong survival in patients with non-small cell lung cancer: A prospective, randomized, placebo-controlled, double-blind, three-arm, multicenter study
Open the record for dataset details and reuse information.
MALDI-MS raw files of primary human lung cancer samples, lung cancer patient derived xenografts and lung cancer mouse models
Open the record for dataset details and reuse information.
Innate immune activation by checkpoint inhibition in patient-derived lung cancer tissues
Open the record for dataset details and reuse information.
3d Virtual Patho-Histology of Lung Tissue from Covid19 Patients based on Phase Contrast X-ray Tomography
<p>X-ray phase contrast tomographys datasets of lung tissue from 6 Covid-19 patients (paraffin embedded unstained tissue), and one control tissue (healthy lung, in fixative solution). The data has been recorded as part of the Covid-19 Call for Proposals at DESY April 2020 at the GINIX instrument, beamline P10 of the PETRAIII storage ring at 8keV. Three different datasets are included in a single tar archive for each sample: (i) overview scan (up to 4mm cross section ) from stitching different tomograms, (ii) 1mm cylindrical punch, and (iii) cone-beam zoom tomogram recorded with waveguide illumination. </p> <p>voxel sizes: (i) 1.3µm, (ii) 650nm, (iii) 167nm. </p> <p>3 datasets per sample, raw format, voxel numbers given in Filename, single (32bit real)</p> <p> </p>
Data from: Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps - a feasibility study
Objective: The aim of this study was to prospectively evaluate the feasibility of monitoring treatment response to chemotherapy in patients with non-small cell lung carcinoma using functional diffusion maps (fDMs). Materials and Methods: This study was approved by the Cantonal Research Ethics Committee and informed written consent was obtained from all patients. Nine patients (mean age = 66 years; range = 53–76 years, 5 females, 4 males) with overall 13 lesions were included. Imaging was performed within two weeks before initiation of chemotherapy and at one, two, and six weeks after initiation of chemotherapy. Imaging included a respiratory-triggered diffusion-weighted sequence including three b-factors (100, 600, and 800 s/mm2). Treatment response was defined by change in tumor diameter on computed tomography (CT) after two cycles of chemotherapy. Changes in the apparent diffusion coefficient (ADC) on a per-lesion basis and the percentages of voxel with significantly increased or decreased ADCs on fDMs were analyzed using repeated measures analysis of variance (ANOVA). Changes in tumor size were used as covariate to examine the ability of ADCs and fDM parameters to predict treatment response. Results: Repeated measures ANOVA revealed that the percentage of voxels with increased ADCs on fDMs (p = 0.002) as well as the mean ADC increase (p = 0.011) were significantly higher in good responders with a large reduction in tumor size on CT. Conclusion: Our results indicate that the percentage of voxels with significantly increased ADCs on fDMs seems to be a promising biomarker for early prediction of treatment response in patients with non-small cell lung carcinoma. Contrary to averaged values, this approach allows the spatial heterogeneity of treatment response to be resolved.
Lung250M-4B: A Combined 3D Dataset for CT- and Point Cloud-Based Intra-Patient Lung Registration
<p>Point Cloud Data from the Lung250M-4B dataset.</p><p>Visit https://github.com/multimodallearning/Lung250M-4B for image data and associated code.</p>
Genomic features of lung cancer patients in Indonesia's National Cancer Center
<p><strong>Introduction:</strong> Advances in molecular biology bring advantages to lung cancer management. Moreover, high-throughput molecular tests are currently useful for revealing genetic variations among lung cancer patients. We investigated the genomics profile of the lung cancer patients at the National Cancer Centre of Indonesia.</p> <p><strong>Methods:</strong> A retrospective study enrolled 627 tissue biopsy samples using real time polymerase chain reaction (RT-PCR) and 80 circulating tumour DNA (ctDNA) liquid biopsy samples using next-generation sequencing (NGS) from lung cancer patients admitted to the Dharmais Cancer Hospital from January 2018 to December 2022. Data were obtained from medical records. Data statistically analysed with p<0.05 is considered significant.</p> <p><strong>Result:</strong> The <em>EGFR</em> test results revealed by RT-PCR were wild type (51.5%), single variant (38.8%), double variant (8.3%), and triple variant (1.4%), with 18.66% L85R, 18.22% Ex19del, and 11.08% L861Q variant. Liquid biopsy ctDNA using NGS showed only 2.5% <em>EGFR</em> wild type, 62.5% single variant and 35% co-variant, with <em>EGFR/TP53</em> and <em>EGFR/PIK3CA</em> as the highest.</p> <p><strong>Conclusion:</strong> EGFR variants are the most found in our centre. Liquid biopsy with ctDNA using NGS examination could detect broad variants and co-variants that will influence the treatment planning.</p>
Disease trajectories in hospitalized COVID-19 patients are predicted by clinical and peripheral blood signatures representing distinct lung pathologies
<p><span>COVID-19 is characterized by a broad range of symptoms and disease trajectories. Understanding the correlation between clinical biomarkers and lung pathology over the course of acute COVID-19 is necessary to understand its diverse pathogenesis and inform more precise and effective treatments. Here, we present an integrated analysis of longitudinal clinical parameters, peripheral blood biomarkers, and lung pathology in COVID-19 patients from the Brazilian Amazon. We identified core clinical and peripheral blood signatures differentiating disease progression between recovered patients from severe disease and fatal cases. Signatures were heterogenous among fatal cases yet clustered into two patient groups: “early death” (< 15 days of disease until death) and “late death” (> 15 days). Progression to early death was characterized systemically and in lung histopathology by rapid, intense endothelial and myeloid activation/chemoattraction and presence of thrombi, associated with SARS-CoV-2<sup>+</sup> macrophages. In contrast, progression to late death was associated with fibrosis, apoptosis and abundant SARS-CoV-2<sup>+</sup> epithelial cells in post-mortem lung, with cytotoxicity, interferon and Th17 signatures only detectable in the peripheral blood 2 weeks into hospitalization. Progression to recovery was associated with higher lymphocyte counts, Th2 and anti-inflammatory-mediated responses. By integrating ante-mortem longitudinal systemic and spatial single-cell lung signatures, we defined an enhanced set of prognostic clinical parameters predicting disease outcome for guiding more precise and optimal treatments.</span><span> Finally, this study represents a major advance in the investigation of acute respiratory infections by integrating serial clinical data and peripheral blood samples with histopathological and </span><span>spatially-resolved single-cell </span><span>analyses of post-mortem lung samples.</span></p>
Blood memory CD8 T cell phenotypes in lung cancer patients predict immune checkpoint treatment responses
<p>Rscript for figure generation and data analysis:</p> <p>GenerateFigures.R</p> <p> </p> <p>Seurat objects containing processed data after quality control:</p> <p><a href="../api/records/10867209/draft/files/NCCS_For_Zenodo.RDS/content" target="_blank" rel="noopener noreferrer">NCCS_For_Zenodo.RDS</a> - NCCS discovery cohort.</p> <p><a href="../api/records/10867209/draft/files/Pavia_For_Zenodo.RDS/content" target="_blank" rel="noopener noreferrer">Pavia_For_Zenodo.RDS</a> - Pavia validation cohort.</p> <p> </p> <p>RDS files containing DEGs or differentially abundant surface markers:</p> <p>TestResults2Groups.rds - Cell type specific LTR vs Non Responder DEG </p> <p>TestResults2GroupsADT.rds - Cell type specific LTR vs Non Responder differential surface markers</p> <p>TestResults2GroupsLungOnly.rds - Cell type specific LTR vs Non Responder DEG on lung samples only</p> <p>TestResults2GroupsLungOnlyADT.rds - Cell type specific LTR vs Non Responder differential surface markers on lung samples only</p> <p>TestResults3Groups.rds - Cell type specific LTR vs R vs Non Responder differential DEG</p> <p>TestResults3GroupsGeneralADT.rds - Across cell type LTR vs R vs Non Responder differential surface markers</p> <p>TestResults2GroupsGeneralRNA.rds - Across cell type LTR vs Non Responder DEG </p> <p>TestResults2GroupsGeneralADT.rds - Across cell type LTR vs Non Responder differential surface markers</p> <p>TestResults2GroupsLungOnlyGeneralRNA.rds - Across cell type LTR vs Non Responder DEG on lung samples only</p> <p>TestResults2GroupsLungOnlyGeneralADT.rds - Across cell type LTR vs Non Responder differential surface markers on lung samples only</p> <p>TestResults3GroupsGeneralRNA.rds - Across cell type LTR vs R vs Non Responder differential DEG</p> <p>TestResults3GroupsGeneralADT.rds - Across cell type LTR vs R vs Non Responder differential surface markers</p> <p> </p> <p>Logistic regression models trained on the NCCS discovery cohort:</p> <p>PerCellPredictions <CellType> * - Celltype specific models predicting either LTR, R or control group trained on all NCCS samples</p> <p>PerCellPredictions_2Groups_LungOnly <CellType> * - Celltype specific models predicting either LTR or NonResponder group, trained on lung samples only.</p> <p>PerCellPredictions_2Groups_<CellType> * - Celltype specific models predicting either LTR or NonResponder trained on all NCCS samples</p>
Quantitative Evaluation of COVID-19 Pneumonia Lung Extension by Specific Software and Correlation with Patient Clinical Outcome
<p>Quantitative Evaluation of COVID-19 Pneumonia Lung Extension by Specific Software and Correlation with Patient Clinical Outcome</p> <p>Dataset regarding lung extension of covid 19 </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.